Walker Process

A Walker Process claim is an antitrust counterclaim under Sherman Act § 2 (monopolization or attempted monopolization) arising from a patent that was obtained by fraud on the USPTO. The doctrine takes its name from Walker Process Equipment, Inc. v. Food Machinery & Chemical Corp. (S.Ct. 1965), where the Supreme Court held that an antitrust claim based on patent fraud is actionable — if the patent owner has market power, enforcement of a fraudulently obtained patent can constitute illegal monopolization. POLICY BASIS: the patent system grants a limited monopoly in exchange for public disclosure; the Sherman Act condemns monopolization achieved by improper means; obtaining a patent by deception and then weaponizing it against competition combines both wrongs; Walker Process creates an antitrust remedy for the most egregious patent procurement misconduct. RELATIONSHIP TO INEQUITABLE CONDUCT: both doctrines involve misconduct before the USPTO; inequitable conduct (a defense in patent litigation) renders the patent unenforceable if there was intent to deceive the examiner; Walker Process creates an AFFIRMATIVE antitrust COUNTERCLAIM requiring proof of intentional fraud (not merely inequitable conduct) plus antitrust injury and market power; the two doctrines overlap but are not identical — proof sufficient for inequitable conduct may fall short of Walker Process fraud, and Walker Process requires the additional antitrust elements of market power and antitrust injury; REMEDIES: Walker Process enables treble damages, attorneys' fees, and injunctive relief under Sherman Act § 4 — far more potent than mere unenforceability from inequitable conduct.

A successful Walker Process antitrust claim requires proving all of the following elements: (1) FRAUD ON THE USPTO — the patent was obtained by intentional fraud on the Patent Office; this requires proof of the common law elements of fraud: (a) false representation of a material fact; (b) knowledge of the falsity (scienter); (c) intent to deceive the USPTO; (d) reliance by the USPTO examiner; (e) issuance of the patent as a result; the fraud must be intentional — mere negligence or even inequitable conduct short of fraud is insufficient for Walker Process; common examples include: submitting false test data; concealing material prior art known to be material while withholding it with intent to deceive; making affirmative false statements about the prior art to overcome a rejection; making false declarations of inventorship; (2) PATENT ENFORCEMENT — the patent owner must have actually enforced (or attempted to enforce) the fraudulently obtained patent; filing a lawsuit or threatening infringement proceedings suffices; (3) RELEVANT MARKET AND MARKET POWER — the defendant must define a relevant antitrust market and prove the patentee has monopoly power (> 70% market share) in that market, or for attempted monopolization, a dangerous probability of achieving monopoly power; (4) ANTITRUST INJURY — the plaintiff must have suffered an antitrust injury causally connected to the fraudulent patent enforcement (e.g., competitive harm from being excluded or forced to pay excessive royalties); (5) CAUSATION — the fraudulent enforcement was the but-for cause of competitive harm; NOTE: the Supreme Court did not specify whether the patent must be the only basis for market power — circuit courts have generally required that the patent itself be the basis for (or a significant contributor to) the market power.

Walker Process fraud and inequitable conduct both arise from misconduct before the USPTO but differ significantly: INEQUITABLE CONDUCT: the standard is lower — materiality plus intent to deceive (Therasense: but-for materiality + specific intent to deceive the USPTO); the remedy is only unenforceability (patent cannot be enforced in the lawsuit); it is a defense in the patent case, not an independent antitrust claim; it does not require proof of market power or antitrust injury; WALKER PROCESS FRAUD: requires the higher standard of common law fraud — intentional false statements with scienter, not merely omitting material information; the remedy is treble antitrust damages, fees, and injunctive relief; it is an AFFIRMATIVE COUNTERCLAIM (and sometimes an independent cause of action); it requires proof of relevant market, market power, and antitrust injury in addition to the fraud; CAN BOTH APPLY: yes — the same conduct may satisfy both standards; if the misconduct constitutes fraud, it likely also satisfies inequitable conduct; the defendant can plead both; strategic choice: in a case with strong evidence of intentional fraud AND market power, Walker Process adds substantial damage exposure; if market power is weak, inequitable conduct alone may be the better vehicle for unenforceability; MATERIALITY: for inequitable conduct, but-for materiality is required (patent would not have issued); for Walker Process, the fraud must have caused the patent to issue; the test is similar — the misrepresentation or omission must have been material to issuance.

Courts have found Walker Process claims to survive on various fact patterns, though the high proof bar means many fail: EXAMPLES OF COGNIZABLE FRAUD: (1) submitting false data or fabricated test results to demonstrate that the claimed invention works as described, when the actual data would not have supported patentability; (2) omitting known prior art that an examiner would have found material — but the omission must be accompanied by evidence of INTENT to deceive, not just knowledge of the prior art; (3) making materially false statements in declarations (§ 1.131 swearing behind dates; § 1.132 experimental data) when the applicant knew the statements were false; (4) misrepresenting the results of comparative tests to establish unexpected results in response to a § 103 obviousness rejection; (5) inequitable conduct plus evidence of an intentional scheme to deceive (e.g., emails or communications showing deliberate strategy to withhold art from the examiner); WHAT IS NOT ENOUGH: (1) mere negligent failure to conduct thorough prior art searches; (2) failure to disclose art that the patent owner didn't actually know was material; (3) aggressive claim drafting that later turns out to be broader than the disclosure supports; (4) omitting prior art that the examiner independently cited — no causation; (5) inequitable conduct without the scienter showing — Therasense requires specific intent, but Walker Process requires the even higher bar of intentional fraud; PLEADING REQUIREMENTS: Walker Process fraud must be pled with particularity under FRCP 9(b) — vague allegations of undisclosed art or unsupported assertions of fraud are routinely dismissed.

Walker Process claims are a powerful — but high-risk — litigation tool: STRATEGIC USES: (1) LEVERAGE IN SETTLEMENT: a well-pleaded Walker Process counterclaim (with credible fraud evidence and market power) dramatically increases the settlement value for the defendant; the threat of treble antitrust damages on top of litigation costs makes settlement more attractive to the patent plaintiff; (2) AFFIRMATIVE DAMAGES: if the defendant can prove Walker Process, they can recover treble damages for competitive harm caused by the fraudulent enforcement — this flips the case from pure defense to recovery; (3) ATTORNEY FEE SHIFTING: antitrust and patent exceptional-case fee awards together can make aggressive enforcement expensive for patent owners; (4) EXPOSING MISCONDUCT: even unsuccessful Walker Process claims can expose the patent owner's internal prosecution decisions through antitrust discovery; RISKS AND LIMITATIONS: (1) HIGH PROOF BAR: proving intentional fraud (not just inequitable conduct) is difficult without internal communications or documents showing conscious wrongdoing; (2) MARKET POWER CHALLENGE: defining a relevant market narrow enough to show monopoly power in a patent case is often contested and expert-intensive; (3) COUNTERCLAIM EXPOSURE: a failed Walker Process claim may result in sanctions or fee shifting if the court finds it was objectively unreasonable (exceptional case); BEST CASES FOR WALKER PROCESS: patent acquired through licensing/M&A from an assignee with strong evidence of original prosecution fraud; cases with access to internal communications (prosecution counsel emails) showing deliberate suppression of prior art; cases where prior art was well-known in the industry and the patentee clearly knew about it; pharma and medical device markets where the patent creates a discrete product market making market power easier to establish.